

EHA2026 Congress

June 11–14, 2026
Stockholm, Sweden



 **MultipleMyelomaHub**

TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Thank you to the funders of the Multiple Myeloma Hub. All content is developed independently by SES in collaboration with an expert steering committee. Funders are allowed no influence. A full list of our current funders can be found at MultipleMyelomaHub.com.

EHA2026: Top abstracts in multiple myeloma and other plasma cell dyscrasias

June 11–14, 2026

Oral presentations: Friday, June 12

Abstract	Title	Presenter	Time (CEST)
S205 View	Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study	Cyrille Touzeau	17:15–17:30
S207 View	Aggressive smoldering curative approach evaluating novel therapies (ASCENT): A phase 2 trial of induction, consolidation, and maintenance in high-risk smoldering multiple myeloma	Shaji Kumar	17:45–18:00
S208 View	Initial efficacy and safety data from the phase 1/2 LINKER-AL2 study of linvoseltamab (Linvo) monotherapy in patients with relapsed or refractory (RR) systemic light chain (AL) amyloidosis	Ashutosh Wechalekar	18:00–18:15

Oral presentations: Saturday, June 13

Abstract	Title	Presenter	Time (CEST)
S100 View	Phase 3, randomized study of talquetamab (Tal) plus daratumumab (Dara) ± pomalidomide (Pom) vs Dara plus Pom and dexamethasone (DPd) in relapsed/refractory multiple myeloma (RRMM): MonumentAL-3	Peter Voorhees	12:15–12:30
S195 View	MAJESTEC-9: A phase 3 study of teclistamab monotherapy vs pomalidomide/bortezomib/dexamethasone or carfilzomib/dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM)	Cyrille Touzeau	17:15–17:30
S196 View	Daratumumab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: Final analysis of transplant-ineligible patients in the phase 3 CEPHEUS study	Saad Z. Usmani	17:30–17:45
S198 View	Teclistamab plus daratumumab (Tec-Dara) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Analysis of MajesTEC-3 based on cytogenetic and functional risk	Rahul Banerjee	18:00–18:15
S199 View	Safety and efficacy of iberdomide-based quadruplet for patients with newly diagnosed multiple myeloma: The IDEAL phase I/II trial results	Prashant Kapoor	18:15–18:30

Oral presentations: Sunday, June 14

Abstract	Title	Presenter	Time (CEST)
LB5004 View	Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial	Meletios Dimopoulos	10:00–10:15

Posters

Abstract	Title	Presenter	Date and time (CEST)
PF762 View	DREAMM-9 final analysis: Belantamab mafodotin (belamaf), bortezomib, lenalidomide, and dexamethasone (BVRd) for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM)	Enrique M. Ocio	Friday, June 12, from 18:45
PF787 View	Whole genome sequencing of multiple myeloma cells with a novel clinical assay uncovers diversity of genetic alterations underlying immunotherapy resistance	Bruno Paiva	Friday, June 12, from 18:45
PF766 View	Isatuximab–Rd induction followed by Isa-R maintenance compared to Rd induction followed by R maintenance in elderly pts with NDMM with emphasis on frail and non-frail pts (AGMT MM04 trial)	Heinz Ludwig	Friday, June 12, from 18:45
PS1862 View	Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: Updated 4-year results of the phase 3 DREAMM-7 trial	Vania Hungria	Saturday, June 13, from 18:45
PS1865 View	Cevostamab (FcRH5xCD3 bispecific antibody) induces durable responses in patients with late-line RRMM who have received prior BCMA-targeted CAR T-cell therapy: Expansion results from the CAMMA 2 study	Shaji Kumar	Saturday, June 13, from 18:45
PS1875 View	Iberdomide plus daratumumab and dexamethasone in newly diagnosed multiple myeloma (NDMM) by renal function: Subgroup analysis of the CC-220-MM-001 trial	Anna Sureda	Saturday, June 13, from 18:45
PS1877 View	Belantamab mafodotin, pomalidomide, and dexamethasone (BPd) demonstrated improved outcomes as second-line therapy vs pomalidomide, bortezomib, and dexamethasone (PVd) in patients with multiple myeloma	Meral Beksaç	Saturday, June 13, from 18:45
PS1882 View	Establishing fully outpatient ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: First clinical data from Europe	Tim Richardson	Saturday, June 13, from 18:45
PS1896 View	Elranatamab in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-20 trial	C. Ola Landgren	Saturday, June 13, from 18:45
PS1919 View	Outpatient step-up dosing of teclistamab or talquetamab with prophylactic tocilizumab in patients with relapsed/refractory multiple myeloma: Real-world evidence from a large US cancer center	Cesar Rodriguez	Saturday, June 13, from 18:45



#EHA2026

Follow us on X to keep up to date
with the latest from the congress

@MM_Hub

 **MultipleMyelomaHub**

Brought to you by

